DDInter764 DDInter899
Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Flurbiprofen {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Flurbiprofen {u} (Compound) resembles {v} (Compound) Tiaprofenic acid
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Flurbiprofen {u} (Compound) binds {v} (Gene) UGT1A1
Flurbiprofen {u} (Compound) upregulates {v} (Gene) IKBKE
Flurbiprofen {u} (Compound) palliates {v} (Disease) osteoarthritis
Flurbiprofen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Flurbiprofen {u} (Compound) downregulates {v} (Gene) RRP12
Flurbiprofen {u} (Compound) causes {v} (Side Effect) Inflammatory bowel disease
Flurbiprofen (Compound) resembles L-Phenylalanine (Compound)
Flurbiprofen (Compound) resembles Tiaprofenic acid (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Flurbiprofen (Compound) binds UGT1A1 (Gene)
Flurbiprofen (Compound) upregulates IKBKE (Gene)
Flurbiprofen (Compound) palliates osteoarthritis (Disease)
Flurbiprofen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Flurbiprofen (Compound) downregulates RRP12 (Gene)
Flurbiprofen (Compound) causes Inflammatory bowel disease (Side Effect)